Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resis...
Guardado en:
Publicado: |
2018
|
---|---|
Materias: | |
Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07248741_v35_n11_p_Grotz http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz |
Aporte de: |